Segment & Geographic Data
Quant-Grade Normalized (live API)
API & CSV Delivery
Akebia Therapeutics Inc's Business Segments
Akebia Therapeutics Inc's reported revenue by business segment and by geographic region, quarterly and annual, normalized against the consolidated income statement. Free below: the top 3 rows per table, this quarter and this fiscal year. Subscriber access adds the full segment history and operating income by segment.
Segment Data As of Q1 FY2026
Reportable Segments
1
Largest Segment
Reportable
Total Revenue
$ 54
Regions Reported
-
Revenue Share by Reportable Segment - Q1 FY2026
- Reportable100%
Revenue by Reportable Segment - Q1 FY2026
| Segment | Revenue (Millions) | % of Total |
|---|---|---|
| Reportable | $ 54 | 100% |
Revenue by Product & Service Category - Q1 FY2026
- Product97.1%
- Auryxia67.6%
- Vafseo29.5%
- License collaboration and other revenue2.9%
Revenue by Product & Service Category - Q1 FY2026
| Category | Revenue (Millions) | % of Total |
|---|---|---|
| Product | $ 52 | 97.1% |
| Auryxia | $ 36 | 67.6% |
| Vafseo | $ 16 | 29.5% |
Product and service categories are a supplemental disclosure and are not required to sum to consolidated revenue or to the reportable segments above.
1 more categories available
Sign in to unlock the full Akebia Therapeutics Inc dataset.
Description of Akebia Therapeutics Inc
Akebia Therapeutics Inc is a biopharmaceutical company that focuses on the development and commercialization of novel therapeutics for patients with kidney diseases. The company is headquartered in Cambridge, Massachusetts, and has a subsidiary in Tokyo, Japan. Founded in 2007, Akebia's mission is to make a meaningful difference in the lives of patients with chronic kidney disease (CKD) by advancing the development of innovative therapies.
The company's lead compound is vadadustat, an oral hypoxia-inducible factor (HIF) prolyl hydroxylase (PH) inhibitor that is designed to mimic the body's natural response to hypoxia (low oxygen levels) by stimulating erythropoiesis (the production of red blood cells). Kidney disease patients often suffer from anemia, which is a shortage of red blood cells, and vadadustat is aimed at treating this condition in CKD patients.
In clinical trials, vadadustat has demonstrated efficacy and safety in increasing hemoglobin levels in both incident and prevalent CKD patients with anemia. Akebia is conducting Phase 3 trials to evaluate the long-term safety and efficacy of vadadustat compared to conventional therapy with erythropoiesis-stimulating agents (ESAs) for the treatment of anemia associated with CKD.
Aside from vadadustat, Akebia is also exploring other drug candidates for the treatment of kidney diseases. These include AKB-6899, a selective dopamine D1 receptor agonist, and AKB-5169, a selective HIF-2 alpha inhibitor.
Akebia has established partnerships with several pharmaceutical companies to develop and commercialize vadadustat in various regions around the world. Partnerships include Otsuka Pharmaceutical Co. Ltd. for Japan, Mitsubishi Tanabe Pharma Corporation for Asia, and Vifor Pharma Group for Europe, Middle East, and Africa.
Overall, Akebia Therapeutics Inc is a biopharmaceutical company dedicated to developing innovative therapies for patients with kidney diseases. With its lead compound vadadustat, the company is poised to make a significant impact on the treatment of anemia in CKD patients, with the potential to improve patient outcomes and quality of life.
The company's lead compound is vadadustat, an oral hypoxia-inducible factor (HIF) prolyl hydroxylase (PH) inhibitor that is designed to mimic the body's natural response to hypoxia (low oxygen levels) by stimulating erythropoiesis (the production of red blood cells). Kidney disease patients often suffer from anemia, which is a shortage of red blood cells, and vadadustat is aimed at treating this condition in CKD patients.
In clinical trials, vadadustat has demonstrated efficacy and safety in increasing hemoglobin levels in both incident and prevalent CKD patients with anemia. Akebia is conducting Phase 3 trials to evaluate the long-term safety and efficacy of vadadustat compared to conventional therapy with erythropoiesis-stimulating agents (ESAs) for the treatment of anemia associated with CKD.
Aside from vadadustat, Akebia is also exploring other drug candidates for the treatment of kidney diseases. These include AKB-6899, a selective dopamine D1 receptor agonist, and AKB-5169, a selective HIF-2 alpha inhibitor.
Akebia has established partnerships with several pharmaceutical companies to develop and commercialize vadadustat in various regions around the world. Partnerships include Otsuka Pharmaceutical Co. Ltd. for Japan, Mitsubishi Tanabe Pharma Corporation for Asia, and Vifor Pharma Group for Europe, Middle East, and Africa.
Overall, Akebia Therapeutics Inc is a biopharmaceutical company dedicated to developing innovative therapies for patients with kidney diseases. With its lead compound vadadustat, the company is poised to make a significant impact on the treatment of anemia in CKD patients, with the potential to improve patient outcomes and quality of life.
Akebia Therapeutics Inc operates within the biopharmaceutical landscape, focusing heavily on the development and commercialization of therapies specifically aimed at treating patients suffering from kidney diseases. The companys operations are streamlined under a single segment, allowing for a concentrated approach in addressing the unique challenges posed by chronic kidney disease (CKD) and its associated complications, such as anemia.
Segments
Akebia Therapeutics is strategically positioned within the biopharmaceutical industry, emphasizing innovative therapeutic solutions for kidney diseases. The single-segment operational model allows for enhanced resource allocation and focused research and development efforts. This enables Akebia to maintain a sharp focus on its specialized area, thereby optimizing its potential to impact patient outcomes positively. The concentration on kidney health is critical, given the rising prevalence of chronic kidney disease and its significant impact on patients quality of life.
Products
At the forefront of Akebias product portfolio is Vadadustat, an innovative oral therapeutic designed specifically for the treatment of anemia associated with chronic kidney disease.
Vadadustat
- Mechanism of Action: Vadadustat is classified as a hypoxia-inducible factor (HIF) prolyl hydroxylase inhibitor (PHI). This mechanism stimulates the body’s natural production of erythropoietin, a key hormone responsible for the formation of red blood cells. By enhancing erythropoietin levels, Vadadustat facilitates an increase in hemoglobin concentrations in the bloodstream, which is crucial for restoring and maintaining proper oxygen levels in the body.
- Formulation and Administration: Vadadustat is administered orally, offering a convenient alternative to injectable therapies commonly used for managing anemia in CKD patients. This ease of use aims to improve patient compliance and overall treatment experience.
- Potential Impact: Vadadustat holds the promise of being a first-in-class oral agent for anemia in the CKD population, thus potentially revolutionizing treatment protocols. It not only addresses the symptomatic aspect of anemia but also targets the underlying mechanisms that lead to reduced erythropoietin production and, consequently, anemia in patients with kidney impairment.
The introduction and development of Vadadustat underline Akebia’s commitment to enhancing therapeutic options and improving the lives of patients dealing with anemia related to chronic kidney disease.
Services
In addition to their pharmacological innovations, Akebia Therapeutics provides a range of supportive services designed to optimize the treatment journey for patients utilizing Vadadustat.
AkebiaCares Patient Support Program
- Financial Assistance: AkebiaCares is a robust support program that assists patients with co-payment obligations. This financial support is critical in easing the burden of medication costs, ensuring that patients can access Vadadustat without facing significant out-of-pocket expenses.
- Access to Therapy: The program facilitates streamlined access to Vadadustat, helping patients navigate the complexities of obtaining their prescribed therapy. This may involve coordination with pharmacies, healthcare providers, and insurance companies to ensure that patients receive their medications without undue delay.
- Educational Resources: Akebia provides comprehensive educational materials about chronic kidney disease and the mechanisms of anemia, enabling patients and healthcare providers to better understand the condition. This includes information on the implications of CKD, treatment modalities, and lifestyle recommendations that may enhance overall health and well-being.
- Collaboration with Healthcare Professionals: The companys efforts involve partnerships with healthcare professionals to foster better communication and understanding of the treatment options for anemia associated with CKD. This collaborative approach aims to enhance patient management strategies and optimize health outcomes.
By combining innovative products with comprehensive support services, Akebia Therapeutics Inc positions itself as a key player in the biopharmaceutical sector, dedicated to improving the lives of patients facing the challenges of chronic kidney disease and its complications. The focused development of therapeutic options, alongside robust patient support mechanisms, underscores Akebia’s mission to make a meaningful impact in the lives of those suffering from kidney disorders.
Segments
Akebia Therapeutics is strategically positioned within the biopharmaceutical industry, emphasizing innovative therapeutic solutions for kidney diseases. The single-segment operational model allows for enhanced resource allocation and focused research and development efforts. This enables Akebia to maintain a sharp focus on its specialized area, thereby optimizing its potential to impact patient outcomes positively. The concentration on kidney health is critical, given the rising prevalence of chronic kidney disease and its significant impact on patients quality of life.
Products
At the forefront of Akebias product portfolio is Vadadustat, an innovative oral therapeutic designed specifically for the treatment of anemia associated with chronic kidney disease.
Vadadustat
- Mechanism of Action: Vadadustat is classified as a hypoxia-inducible factor (HIF) prolyl hydroxylase inhibitor (PHI). This mechanism stimulates the body’s natural production of erythropoietin, a key hormone responsible for the formation of red blood cells. By enhancing erythropoietin levels, Vadadustat facilitates an increase in hemoglobin concentrations in the bloodstream, which is crucial for restoring and maintaining proper oxygen levels in the body.
- Formulation and Administration: Vadadustat is administered orally, offering a convenient alternative to injectable therapies commonly used for managing anemia in CKD patients. This ease of use aims to improve patient compliance and overall treatment experience.
- Potential Impact: Vadadustat holds the promise of being a first-in-class oral agent for anemia in the CKD population, thus potentially revolutionizing treatment protocols. It not only addresses the symptomatic aspect of anemia but also targets the underlying mechanisms that lead to reduced erythropoietin production and, consequently, anemia in patients with kidney impairment.
The introduction and development of Vadadustat underline Akebia’s commitment to enhancing therapeutic options and improving the lives of patients dealing with anemia related to chronic kidney disease.
Services
In addition to their pharmacological innovations, Akebia Therapeutics provides a range of supportive services designed to optimize the treatment journey for patients utilizing Vadadustat.
AkebiaCares Patient Support Program
- Financial Assistance: AkebiaCares is a robust support program that assists patients with co-payment obligations. This financial support is critical in easing the burden of medication costs, ensuring that patients can access Vadadustat without facing significant out-of-pocket expenses.
- Access to Therapy: The program facilitates streamlined access to Vadadustat, helping patients navigate the complexities of obtaining their prescribed therapy. This may involve coordination with pharmacies, healthcare providers, and insurance companies to ensure that patients receive their medications without undue delay.
- Educational Resources: Akebia provides comprehensive educational materials about chronic kidney disease and the mechanisms of anemia, enabling patients and healthcare providers to better understand the condition. This includes information on the implications of CKD, treatment modalities, and lifestyle recommendations that may enhance overall health and well-being.
- Collaboration with Healthcare Professionals: The companys efforts involve partnerships with healthcare professionals to foster better communication and understanding of the treatment options for anemia associated with CKD. This collaborative approach aims to enhance patient management strategies and optimize health outcomes.
By combining innovative products with comprehensive support services, Akebia Therapeutics Inc positions itself as a key player in the biopharmaceutical sector, dedicated to improving the lives of patients facing the challenges of chronic kidney disease and its complications. The focused development of therapeutic options, alongside robust patient support mechanisms, underscores Akebia’s mission to make a meaningful impact in the lives of those suffering from kidney disorders.